StockNews.com Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to “Hold”

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Several other brokerages also recently commented on SGMO. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday. Barclays raised their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday.

Sangamo Therapeutics Stock Down 4.7 %

NASDAQ SGMO opened at $2.05 on Thursday. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The company has a fifty day moving average of $1.33 and a two-hundred day moving average of $0.86. The firm has a market capitalization of $427.67 million, a price-to-earnings ratio of -2.73 and a beta of 1.10.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System boosted its holdings in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the last quarter. Meritage Portfolio Management boosted its stake in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Sangamo Therapeutics in the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.